FDMT Stock - 4D Molecular Therapeutics, Inc.
Unlock GoAI Insights for FDMT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $37,000 | $20.72M | $3.13M | $18.04M | $13.61M |
| Gross Profit | $37,000 | $-76,373,000 | $-77,124,000 | $-43,322,000 | $-39,426,000 |
| Gross Margin | 100.0% | -368.5% | -2464.8% | -240.2% | -289.6% |
| Operating Income | $-187,841,000 | $-112,867,000 | $-110,032,000 | $-71,333,000 | $-56,664,000 |
| Net Income | $-160,868,000 | $-100,837,000 | $-107,494,000 | $-71,317,000 | $-56,693,000 |
| Net Margin | -434778.4% | -486.6% | -3435.4% | -395.4% | -416.5% |
| EPS | $-2.98 | $-2.58 | $-3.12 | $-2.46 | $-2.12 |
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Visit WebsiteEarnings History & Surprises
FDMTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.53 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.02 | $-1.01 | +1.0% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.88 | $-0.98 | -11.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.84 | $-0.86 | -2.4% | ✗ MISS |
Q1 2025 | Feb 28, 2025 | $-0.80 | $-0.90 | -12.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.67 | $-0.79 | -17.9% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.72 | $-0.63 | +12.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.73 | $-0.66 | +9.6% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $-0.68 | $-0.77 | -13.2% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.67 | $-0.24 | +64.2% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.77 | $-0.77 | 0.0% | = MET |
Q2 2023 | May 10, 2023 | $-0.88 | $-0.88 | 0.0% | = MET |
Q1 2023 | Mar 15, 2023 | $-0.75 | $-0.84 | -12.0% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.85 | $-0.79 | +7.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.78 | $-0.87 | -11.5% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.73 | $-0.82 | -12.3% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.82 | $-0.85 | -3.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.83 | $-0.82 | +1.2% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.71 | $-0.28 | +60.6% | ✓ BEAT |
Latest News
Frequently Asked Questions about FDMT
What is FDMT's current stock price?
What is the analyst price target for FDMT?
What sector is 4D Molecular Therapeutics, Inc. in?
What is FDMT's market cap?
Does FDMT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to FDMT for comparison